^
    2ms
    INTASYL self-delivering RNAi decreases TIGIT expression, enhancing NK cell cytotoxicity: a potential application to increase the efficacy of NK adoptive cell therapy against cancer. (PubMed, Cancer Immunol Immunother)
    Delivering PH-804 to NK cells before ACT has emerged as a promising strategy to counter TIGIT inhibition, thereby improving the antitumor response. This approach offers the potential for more potent off-the-shelf products for adoptive cell therapy, particularly for hematological malignancies.
    Journal • IO biomarker
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    TIGIT expression
    |
    PH-804 TME
    2years
    PH-804, an INTASYL self-delivering RNAi compound that targets TIGIT enhances NK cell cytotoxicity to tumor cells (SITC 2022)
    Conclusions Here, we demonstrate the potential of PH-804 to improve NK cell potency in ACT. By treating NK cells with INTASYL targeting the inhibitory receptor TIGIT ex vivo, during NK cell expansion, the anti-tumor response of these cells was enhanced potentially resulting in a more effective cell therapy for solid tumors and hematological malignancies.
    IO biomarker
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • IL2 (Interleukin 2) • NCAM1 (Neural cell adhesion molecule 1)
    |
    PH-804 TME